Published in Genes Dev on April 16, 2007
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev (2009) 2.98
TNF/p38α/polycomb signaling to Pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell (2010) 2.89
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81
The promise and peril of chemical probes. Nat Chem Biol (2015) 2.64
Chromatin proteins and modifications as drug targets. Nature (2013) 2.60
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res (2009) 2.31
MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology (2009) 2.17
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Leukaemogenesis: more than mutant genes. Nat Rev Cancer (2010) 2.16
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature (2015) 1.98
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
Maternal diet and aging alter the epigenetic control of a promoter-enhancer interaction at the Hnf4a gene in rat pancreatic islets. Proc Natl Acad Sci U S A (2011) 1.95
Epigenetic analysis of KSHV latent and lytic genomes. PLoS Pathog (2010) 1.94
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget (2010) 1.92
miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb-E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes Dev (2009) 1.91
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer (2010) 1.87
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Epigenetic regulation of heterochromatic DNA stability. Curr Opin Genet Dev (2008) 1.80
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood (2014) 1.75
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol (2013) 1.75
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood (2011) 1.67
PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev (2012) 1.66
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol (2012) 1.59
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer (2011) 1.59
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
Roles of F-box proteins in cancer. Nat Rev Cancer (2014) 1.51
Targeting EZH2 in cancer. Nat Med (2016) 1.51
FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell (2011) 1.49
NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat Chem Biol (2013) 1.46
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res (2011) 1.46
Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet (2010) 1.44
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res (2008) 1.42
De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS One (2014) 1.42
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell (2012) 1.34
A complex Polycomb issue: the two faces of EZH2 in cancer. Genes Dev (2012) 1.32
A histone demethylase is necessary for regeneration in zebrafish. Proc Natl Acad Sci U S A (2009) 1.31
Silencing of Kruppel-like factor 2 by the histone methyltransferase EZH2 in human cancer. Oncogene (2011) 1.31
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer. Oncogene (2010) 1.29
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature (2015) 1.28
TNFalpha-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish S-adenosylhomocysteine hydrolase. Development (2009) 1.28
EZH2 in normal and malignant hematopoiesis. Leukemia (2013) 1.28
EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol Sin (2013) 1.27
Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood (2014) 1.23
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors. PLoS One (2010) 1.17
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest (2010) 1.17
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle (2010) 1.17
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther (2009) 1.16
DNA hypermethylation accompanied by transcriptional repression in follicular lymphoma. Genes Chromosomes Cancer (2009) 1.16
EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One (2011) 1.15
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer (2012) 1.15
EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res (2013) 1.14
(-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. Carcinogenesis (2011) 1.14
Balancing histone methylation activities in psychiatric disorders. Trends Mol Med (2011) 1.14
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2015) 1.14
Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis (2009) 1.14
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.12
Cancer development, progression, and therapy: an epigenetic overview. Int J Mol Sci (2013) 1.10
Drosophila HP1c isoform interacts with the zinc-finger proteins WOC and Relative-of-WOC to regulate gene expression. Genes Dev (2008) 1.10
Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro Oncol (2012) 1.09
The polycomb group protein EZH2 is a novel therapeutic target in tongue cancer. Oncotarget (2013) 1.09
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood (2013) 1.08
Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am (2010) 1.08
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ (2011) 1.07
Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One (2011) 1.07
The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis (2009) 1.06
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res (2011) 1.06
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia (2014) 1.05
Diverse involvement of EZH2 in cancer epigenetics. Am J Transl Res (2015) 1.04
Long-term stability of demethylation after transient exposure to 5-aza-2'-deoxycytidine correlates with sustained RNA polymerase II occupancy. Mol Cancer Res (2010) 1.04
Epigenetic changes in pediatric solid tumors: promising new targets. Clin Cancer Res (2012) 1.03
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila) (2011) 1.03
Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget (2014) 1.03
Oxidative stress and DNA methylation in prostate cancer. Obstet Gynecol Int (2010) 1.03
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep (2013) 1.02
EZH2, an epigenetic driver of prostate cancer. Protein Cell (2013) 1.02
Derivation of new human embryonic stem cell lines reveals rapid epigenetic progression in vitro that can be prevented by chemical modification of chromatin. Hum Mol Genet (2011) 1.02
A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell (2006) 48.80
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature (2000) 18.26
The history of cancer epigenetics. Nat Rev Cancer (2004) 14.38
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev (2006) 14.36
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
The Polycomb group protein EZH2 directly controls DNA methylation. Nature (2005) 13.67
Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell (2002) 13.05
Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer (2006) 11.48
Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell (2001) 11.39
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer (2006) 11.22
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol (2003) 9.13
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell (2002) 8.17
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell (2004) 7.60
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J (2004) 7.32
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell (2004) 6.90
ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell (2002) 6.72
Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov (2006) 6.39
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev (2004) 6.19
Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet (1999) 5.58
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A (2005) 4.57
The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol (2005) 4.52
Retracted Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1. Nature (2002) 4.18
The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu Rev Genet (1995) 4.03
Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst (2003) 3.73
S-Adenosylmethionine and methylation. FASEB J (1996) 3.48
Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol (2004) 3.25
Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell (2006) 3.08
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Histone deacetylase inhibitors. Adv Cancer Res (2004) 2.93
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med (2004) 2.72
Division of labor in polycomb group repression. Trends Biochem Sci (2004) 2.66
A nucleolar isoform of the Fbw7 ubiquitin ligase regulates c-Myc and cell size. Curr Biol (2004) 2.45
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A (2005) 2.07
The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation. Nat Cell Biol (2006) 1.97
Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol (2005) 1.89
Mechanisms of tumor suppression by the SCF(Fbw7). Cell Cycle (2005) 1.88
Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther (2003) 1.84
p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. J Biol Chem (2004) 1.70
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell (2002) 1.56
3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun (1986) 1.48
Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation. Cancer Sci (2006) 1.34
Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res (2002) 1.32
Introduction to Trx-G and Pc-G genes. Methods Enzymol (2004) 1.27
Perturbation of biochemical transmethylations by 3-deazaadenosine in vivo. Biochem Pharmacol (1979) 1.17
Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res (2000) 1.13
Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem (2006) 1.12
Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5'-nor derivatives. Antimicrob Agents Chemother (1989) 1.06
Polycomb silencing and the maintenance of stable chromatin states. Results Probl Cell Differ (1999) 1.05
Rational approaches to the design of antiviral agents based on S-adenosyl-L-homocysteine hydrolase as a molecular target. Antiviral Res (1992) 1.04
Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem (1989) 1.03
Relationship between transient DNA hypomethylation and erythroid differentiation of murine erythroleukemia cells. Proc Natl Acad Sci U S A (1988) 1.01
Activation of collagen IV gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs. Indirect inhibitors of methylation. J Biol Chem (1992) 0.93
Conversion of 3T3-L1 fibroblasts to fat cells by an inhibitor of methylation: effect of 3-deazaadenosine. Science (1981) 0.93
Polycomb silencing mechanisms and genomic programming. Ernst Schering Res Found Workshop (2006) 0.86
Development. Gene-suppressing proteins reveal secrets of stem cells. Science (2006) 0.84
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
A genome-wide association study of global gene expression. Nat Genet (2007) 22.98
Global quantification of mammalian gene expression control. Nature (2011) 22.36
A global map of p53 transcription-factor binding sites in the human genome. Cell (2006) 20.65
International network of cancer genome projects. Nature (2010) 20.35
Genome-wide analysis of mammalian promoter architecture and evolution. Nat Genet (2006) 17.19
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
An oestrogen-receptor-alpha-bound human chromatin interactome. Nature (2009) 12.16
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol (2008) 10.17
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Gene identification signature (GIS) analysis for transcriptome characterization and genome annotation. Nat Methods (2005) 7.87
Mapping human genetic diversity in Asia. Science (2009) 7.40
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Childhood adiposity, adult adiposity, and cardiovascular risk factors. N Engl J Med (2011) 7.16
Cubic AgPb(m)SbTe(2+m): bulk thermoelectric materials with high figure of merit. Science (2004) 7.07
Altered histone acetylation is associated with age-dependent memory impairment in mice. Science (2010) 6.38
Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet (2003) 5.99
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
A human snoRNA with microRNA-like functions. Mol Cell (2008) 5.84
miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res (2011) 5.83
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet (2007) 5.28
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum (2005) 5.18
RNA viral community in human feces: prevalence of plant pathogenic viruses. PLoS Biol (2006) 4.93
Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA (2003) 4.88
Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature (2011) 4.85
Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 4.83
Next-generation DNA sequencing of paired-end tags (PET) for transcriptome and genome analyses. Genome Res (2009) 4.47
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Ligand configurational entropy and protein binding. Proc Natl Acad Sci U S A (2007) 4.33
Transmit and receive transmission line arrays for 7 Tesla parallel imaging. Magn Reson Med (2005) 4.25
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science (2011) 4.16
Repeated polyploidization of Gossypium genomes and the evolution of spinnable cotton fibres. Nature (2012) 4.00
Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell (2012) 3.92
Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics (2009) 3.87
Seven new loci associated with age-related macular degeneration. Nat Genet (2013) 3.81
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet (2008) 3.71
Intradiscal injection therapy for degenerative chronic discogenic low back pain with end plate Modic changes. Spine J (2010) 3.55
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature (2010) 3.54
Array CGH identifies reciprocal 16p13.1 duplications and deletions that predispose to autism and/or mental retardation. Hum Mutat (2007) 3.52
A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc Natl Acad Sci U S A (2007) 3.50
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity (2002) 3.46
Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst (2002) 3.40
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet (2013) 3.39
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
E2-2 protein and Fuchs's corneal dystrophy. N Engl J Med (2010) 3.31
Gene expression in skin and lymphoblastoid cells: Refined statistical method reveals extensive overlap in cis-eQTL signals. Am J Hum Genet (2010) 3.28
Rise in insulin resistance is associated with escalated telomere attrition. Circulation (2005) 3.27
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A (2007) 3.27
Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell (2012) 3.26
Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet (2010) 3.24
Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study. Aging Cell (2008) 3.24
Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. Stem Cells (2005) 3.16
Beta-arrestin-mediated localization of smoothened to the primary cilium. Science (2008) 3.10
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol (2004) 3.10
Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell (2007) 2.96
Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study. Am J Epidemiol (2008) 2.86
Racial diversity of actionable mutations in non-small cell lung cancer. J Thorac Oncol (2015) 2.80
Preperitoneal single-port transvesical enucleation of the prostate (STEP) for large-volume BPH: one-year follow-up of Qmax, IPSS, and QoL. Urology (2012) 2.78
Atrial Fibrillation Is an Independent Predictor of Mortality in Critically Ill Patients. Crit Care Med (2015) 2.77
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
Single-incision transaxillary robotic thyroidectomy: challenges and limitations in a North American population. Otolaryngol Head Neck Surg (2012) 2.76
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res (2006) 2.69
Crystal structure of the specificity domain of ribonuclease P. Nature (2003) 2.69
Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Lancet Oncol (2013) 2.67
A maximum entropy model applied to spatial and temporal correlations from cortical networks in vitro. J Neurosci (2008) 2.65
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet (2010) 2.62
Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res (2014) 2.60
Analysis of wave behavior in lossy dielectric samples at high field. Magn Reson Med (2002) 2.59
Anesthesiologist board certification and patient outcomes. Anesthesiology (2002) 2.57
Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 2.56
Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor. Proc Natl Acad Sci U S A (2005) 2.53
The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol (2010) 2.53
Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol (2005) 2.51
Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis. Am J Hum Genet (2002) 2.47
Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. Proc Natl Acad Sci U S A (2010) 2.47
Tracking the evolution of the SARS coronavirus using high-throughput, high-density resequencing arrays. Genome Res (2004) 2.47
A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell (2008) 2.47
DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell (2008) 2.46
Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension (2004) 2.46
The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol (2009) 2.46
DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell (2012) 2.45
B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell (2010) 2.44
MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res (2010) 2.44
Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol (2008) 2.44
Impact of agricultural management practices on soil organic carbon: simulation of Australian wheat systems. Glob Chang Biol (2013) 2.37